265 related articles for article (PubMed ID: 18519776)
1. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
[TBL] [Abstract][Full Text] [Related]
6. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
10. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
15. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Mom CH; Verweij J; Oldenhuis CN; Gietema JA; Fox NL; Miceli R; Eskens FA; Loos WJ; de Vries EG; Sleijfer S
Clin Cancer Res; 2009 Sep; 15(17):5584-90. PubMed ID: 19690193
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
[TBL] [Abstract][Full Text] [Related]
17. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
Giaccone G; Punt CJ; Ando Y; Ruijter R; Nishi N; Peters M; von Blomberg BM; Scheper RJ; van der Vliet HJ; van den Eertwegh AJ; Roelvink M; Beijnen J; Zwierzina H; Pinedo HM
Clin Cancer Res; 2002 Dec; 8(12):3702-9. PubMed ID: 12473579
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
